BioMarin Pharma (BMRN) reported third quarter earnings of $6.6 million or 6 cents per share on a GAAP basis, higher than $0.8 million or 1 cent per share last year. The company's adjusted earnings were higher at $15.5 million or 13 cents per share compared with $8.2 million or 8 cents per share in the year-ago period.
On average, 19 analysts polled by Thomson Reuters expected earnings of 1 cent per share. Analysts' estimates typically exclude one-time items.
Revenues rose to $80.81 million from the year-ago's $72.65 million. Analysts, on average, expected revenues of $81.92 million.
For the full year, the company guided revenues to $313 million to $327 million, an upward revision from its earlier estimate of $311 million to $336 million. The company also lifted its non-GAAP earnings guidance to $39.8 million to $43.8 million from its earlier estimate of $35.4 million to $41.4 million.
For comments and feedback: editorial@rttnews.com